Recruiting Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation NCT06744647 Conditions AMR, Antibody-mediated Rejection, Biopsy-proven Histologic Scores, +1 more Locations Research Site — Birmingham, Alabama, United States Research Site — Scottsdale, Arizona, United States Research Site — Los Angeles, California, United States Research Site — Orange, California, United States View all 55 locations View more locations Show fewer locations Loading locations... View Trial Details